Publicaciones en colaboración con investigadores/as de Instituto de Parasitología y Biomedicina López Neyra (40)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

  2. Single-cell transcriptomic profiling reveals a pathogenic role of cytotoxic CD4+ T cells in giant cell arteritis

    Journal of Autoimmunity, Vol. 142

2023

  1. Contribution of Telomere Length to Systemic Sclerosis Onset: A Mendelian Randomization Study

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

  2. Identification of Mechanisms by Which Genetic Susceptibility Loci Influence Systemic Sclerosis Risk Using Functional Genomics in Primary T Cells and Monocytes

    Arthritis and Rheumatology, Vol. 75, Núm. 6, pp. 1007-1020

  3. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 6, pp. 837-847

  4. Non-classical circulating monocytes expressing high levels of microsomal prostaglandin E2 synthase-1 tag an aberrant IFN-response in systemic sclerosis

    Journal of Autoimmunity, Vol. 140

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. The Effect of Body Fat Distribution on Systemic Sclerosis

    Journal of Clinical Medicine, Vol. 11, Núm. 20

2021

  1. Fibroblast growth factor-23 is associated with high-density lipoprotein in systemic sclerosis female patients

    Phillippine Journal of Internal Medicine, Vol. 59, Núm. 1, pp. 9-13

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2017

  1. An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis

    Journal of Rheumatology, Vol. 44, Núm. 10, pp. 1453-1457

2016

  1. Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated with Visceral Leishmaniasis

    American Journal of Therapeutics, Vol. 23, Núm. 5, pp. e1193-e1196

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2013

  1. Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients

    Cytokine, Vol. 62, Núm. 2, pp. 232-243

  2. New insight on the Xq28 association with systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 12, pp. 2032-2038

  3. Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression

    PLoS Genetics, Vol. 9, Núm. 10

2012

  1. Altered AKT1 and MAPK1 gene expression on peripheral blood mononuclear cells and correlation with T-helper-transcription factors in Systemic Lupus Erythematosus patients

    Mediators of Inflammation, Vol. 2012

  2. Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 5, pp. 694-699

  3. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases

    DNA and Cell Biology, Vol. 31, Núm. 9, pp. 1486-1491

  4. Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 1, pp. 136-142